DRDC Final Report—Advanced Development of Biomarkers of Sepsis

PDF

Authors
  1. Sensen, C.
  2. Gordon, D.
Corporate Authors
Defence Research and Development Canada, Suffield Research Centre, Ralston AB (CAN);CNA Diagnostics Inc., Calgary AB (CAN)
Abstract
In sepsis, the presence of live microbes in the blood and the clinical symptoms due to such microbes is a hallmark of a potentially lethal infection with biological threat agents and of pathogenic agents in general. Symptomatic sepsis is a late indicator of the infection and is closely associated with high probability of mortality. Biomarkers based on nucleic acids, especially circulating nucleic acids (CNA), offer the potential to assess the stage and degree of sepsis progress. Aggressive treatment and preventative measures can reduce mortality and morbidity due to sepsis, especially if very early, even pre-symptomatic biomarkers of progression are available and can produce an accurate diagnosis of sepsis forming. DRDC and CNAD partnered in 2016 to undertake a project to use new diagnostic methods to identify and diagnose sepsis while the disease is still in a molecular, pre-symptomatic, stage.

Il y a un résumé en français ici.

Keywords
Sepsis;Infection;DNA;Biology Molecular;Diagnostics
Report Number
DRDC-RDDC-2019-C160 — Contract Report
Date of publication
01 Jul 2019
Number of Pages
15
DSTKIM No
CA049670
CANDIS No
810481
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: